Good job for Dr. Lior Shaltiel, PhD and Inbar Paz Benayoun, Adv. for the successful and effective business trip to London last week! Representing the company in an OTC Markets Group event and exploring new opportunities and collaborations! Read More …
Thanks to Nurexone’s performance in recent weeks on the TSXV compared to the market, it has received the badge – shows up on NurExone’s page on the TMX website – and it is now listed on the top healthcare page. Read More …
NurExone Biologic‘s team members Dr. Lior Shaltiel, PhD and Inbar Paz Benayoun, Adv. will attend The OTC Markets Group OTCQX Annual Issuer’s Forum in London. Another great opportunity to expand business strategies, synergies and developments with partners and colleagues! Read More …
We are pleased to introduce NurExone Biologic‘s talented team members, each star at a time..! This time it’s our very own Dr. Irit Dolgopyat, PhD, R&D scientist at NurExone! Check out Irit’s interview about her role and work environment: 1. What R&D scientist do? Designing experiments that systematically characterize and improve the
Company’s analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapies NurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error. Calgary, Alberta–(Newsfile Corp. – December 1, 2022) – NurExone Biologic Inc.
